The latest iteration of Don's plans to sell some assets to move Apabetalone forward seems reasonable to me. That being said I thought it sounded reasonable before to sell an Apabetalone royalty and before that to sell licensing deals etc, etc.  Execution is always lacking.

IMO thus far Don is still in the way long on talk and way short on achievement camp. The fact that any space in the latest Information Circular was devoted to deficient executive compensation was absolutely appalling. The fact that in the past 4 years little to no corporate advancement has taken place should have been mentioned and noted as gross executive/governance non-performance. Mr Cheaper and Faster has accomplished pretty much zero in the recent past and really over 20 years has never consistently achieved anything except erosion of shareholder value. He has probably taken close to or even more in total compensation than the value of the current market cap, that to me is way offside and not exactly a shining example of a job well done. 

I really wish he would stop with the general market statistics as they are extremely misleading. The bottom line is show me another Ph 3 Biotech with serious opportunity that has a 5 cent stock and a roughly 10M usd market cap. I can't find one but I can show you numerous pre-clinical to ph 2 biotechs that currently have market caps 10 to 20 times that of Resverlogix. Even ONC another Canadian biotech whose stock is generally lacklustre has a mc roughly 8x that of RVX.  

Yes biotech has experienced some rough times but very few companies over the last few years have been hit as hard as RVX when their technology is solid. IMO the main reason RVX sits where it does today is years of horrific management. As Don pointed out in the latest presentation Apabetalone (and Zen 3694) have been the subject of much very positive scientific scrutiny yet management has never been able to take care of business and successfully sell the business case to the market. 

I have attached below a link to a summary article from "Genetic Engineering and Biotechnology News" which paints a different, more positive view of the Biotech M&A market than Don does.  With his lack of biotech deal making experience I hope he is not receiving pricing advice from parties more generally interested in potential buyers interests as opposed to the interests of RVX/Zenith.  That being said I really hope that enough science has been successfully accomplished that even Donald Duck could get a fair deal done and move things forward.  IMO the science and shareholders both deserve much better than what has thus far not been delivered by RVX business management.

https://www.genengnews.com/a-lists/top-10-biopharma-takeover-targets-of-2024/